AMAG Pursues Expanded Feraheme Strategy Through Lumara Deal
This article was originally published in The Pink Sheet Daily
The biotech is acquiring privately held Lumara and its women’s health product Makena in hopes of using the salesforce once it expands the indication for its I.V. iron product Feraheme into that market.
You may also be interested in...
AMAG is looking to build out its portfolio by in-licensing or acquiring new commercial products that complement its I.V. iron product Feraheme. The company is in negotiations for multiple assets, while at the same time preparing to launch Feraheme into a broader patient population.
KV clears major hurdle as court okays its chapter 11 reorganization plan, which provides for payment of $23.4 million owed under 2010 Department of Justice settlement and $231.4 million for senior notes; firm’s future remains tied to Makena.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.